home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2834.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
31 lines
Document 2834
DOCN M94A2834
TI Effect of fluconazole (FLU) on the clinical pharmacokinetics of
delavirdine (DLV).
DT 9412
AU Cox S; Anderson RD; Driver M; Carel B; Upjohn Company, Kalamazoo, MI.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):214 (abstract no. PB0284). Unique
Identifier : AIDSLINE ICA10/94369741
AB OBJECTIVE: DLV is a non-nucleoside RT inhibitor with clearance mediated
by Cytochrome P4503A. The purpose of this study was to evaluate the
effects of multiple doses of FLU, a P4503A inhibitor, on the
steady-state pharmacokinetics (PK) of DLV in HIV+patients. METHODS:
Thirteen HIV-1 patients (12 males, 1 female; CD4 = 160-480/mm3) received
DLV 300 mg TID for 30 days. A control group (CON, n = 5) received only
DLV and a FLU group (n = 8) received FLU 400 mg QD on Days 16-30.
RESULTS: DLV PK parameter values did not differ significantly between
the two groups on Day 15 and between Days 15 and 30 for the CON group.
Mean (SD) DLV parameter values from the FLU group are listed below:
TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSION: FLU has no clinically
significant effect on the steady-state PK of DLV.
DE Antiviral Agents/*PHARMACOKINETICS/THERAPEUTIC USE Comparative Study
Cytochrome P-450/METABOLISM Drug Interactions Female
Fluconazole/*PHARMACOKINETICS/THERAPEUTIC USE Half-Life Human HIV
Infections/DRUG THERAPY Indoles/*PHARMACOKINETICS/THERAPEUTIC USE Male
Metabolic Clearance Rate Piperazines/*PHARMACOKINETICS/THERAPEUTIC USE
Reverse Transcriptase/ANTAGONISTS & INHIB MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).